Purisys offers a broad lineup of manufacturing and personnel assets for the development, manufacture and support of pharmaceutical APIs and other chemical synthesis projects. Our flagship, 17,000-square-foot innovation center and manufacturing facility in Athens, GA provides complex, high-barrier custom synthetic chemistry and manufacture of pharmaceutical APIs, as well as comprehensive controlled substance expertise, including: DEA-secure manufacturing, reference standard synthesis and qualification, process development and optimization, analytical method development, optimization, validation and transfer, small-scale cGMP clinical and commercial manufacturing, non-sterile, parenteral processing and milling, product design and development, formulation development and testing, and milling and custom packing. Purisys offers a fully operational global supply chain and export to more than 30 countries—with full international regulatory compliance.
PrecisemAb Biotech Co., Ltd.
PrecisemAb is a spin-off startup of Kaohsiung Medical University. Its core technology, Universal Antibody Lock, can significantly reduce side effects caused by antibody drugs, making antibody therapy safe and effective. [Features of Core Technology (Antibody Lock)] ‧Higher masking ability and removal ability ‧Low immunogenicity ‧Prevention of anti-drug antibody binding ‧Prolonged serum half-life [Lead Product] PSM101, the lead candidate for head and neck cancer and colorectal cancer treatment, will complete stable cell clone generation in 2023 and the non-human primate side effect test in 2024-Q1. [Partnering] Through the (1) co-development of Lock-antibodies and (2) customized Antibody Lock design service, PrecisemAb licenses out Lock-antibodies to global pharma for conducting further clinical trials. | PrecisemAb is a spin-off startup of Kaohsiung Medical University. Its core technology, Universal Antibody Lock, allows antibody drugs, including ADC and bispecific antibodies, to take effect only in diseased areas, solving systemic toxicity and making antibody treatment safe and effective. Now, we are developing the first-in-class antibody drug, PSM101, for advanced head and neck cancer. [Features of Antibody Lock] ★Medication safety with minimized adverse effects ★Elevating treatment efficacy for cancer cure ★Precision-designed for targeting various cancers [Partnering] PrecisemAb licenses Lock-antibodies for further clinical trials through: (1) Co-development of Lock-antibodies: [Oncology] Lock-EGFR, Lock-PD1, Lock-CTLA4, Lock-4-1BB [Autoimmune disease] Lock-TNFα, Lock-IL-1β (2) Customized Antibody Lock Design Service: Including 4 steps to design your own Lock-antibody. | Company Overview Founded in October 2021, PrecisemAb Biotech was established by the late Professor Tian-Lu Cheng, former Vice President of Kaohsiung Medical University (KMU), as a KMU spin-off company. PrecisemAb focuses on applying the exclusively licensed Universal Antibody Lock Technology to develop next-generation precision antibody drugs with high specificity, low side effects, and enhanced therapeutic efficacy. Innovations & Advantages of the Universal Antibody Lock Platform The Universal Antibody Lock Technology integrates a Hinge + Linker structure that connects the VL/VH domains of an antibody. This unique design prevents antibodies from binding to healthy tissues until they reach the tumor microenvironment (TME). The Hinge-based lock, derived from human IgG1, serves as a masking mechanism, reducing unwanted interactions with normal tissues. The Linker, optimized through computational modeling, includes tumor-specific protease cleavage sites and spatial adjustment regions that ensure precise activation in the tumor microenvironment (TME). This mechanism enables antibodies to remain inactive in normal tissues and only activate when exposed to tumor-specific proteases, thereby minimizing off-target toxicity and enhancing therapeutic efficacy. By selectively triggering antibody activation at the tumor site, this technology significantly reduces side effects and improves treatment outcomes, ultimately enhancing patient quality of life. Compared to competing platforms, the Universal Antibody Lock Technology offers several key advantages. First, the human IgG1 hinge-based lock has low immunogenicity, reducing the risk of anti-drug antibody (ADA) formation and avoiding interference with drug efficacy. Second, the platform is highly versatile, allowing seamless integration into monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and bispecific antibodies (BsAbs), which accelerates the development timeline for Lock-antibody drugs. Third, the linker design, incorporating tumor-specific protease cleavage sites and spatial adjustment regions, delivers the highest antibody activation rate globally in TME. The Universal Antibody Lock Technology has been adopted for industry collaboration. In May 2024, GlycoNex Biotech signed a non-exclusive licensing agreement with PrecisemAb, further demonstrating its applicability in antibody drug development. Drug Development (1) PrecisemAb’s lead drug, PSM101 (Lock-EGFR antibody), is designed for EGFR-expressing cancers, including head and neck cancer and colorectal cancer. The drug has successfully completed in vitro and in vivo efficacy and safety studies, cell line development, upstream process optimization (yield: 4.2 g/L), downstream process optimization, formulation research, and accelerated stability testing. PSM101 is planned for IND submission to the US FDA and TFDA in Q4 2026. (2) Additionally, PSM915 (Lock-TNF-α) has been evaluated in Biomedcode’s rheumatoid arthritis (RA) mouse model, demonstrating its ability to suppress RA disease progression and improve drug safety.
Polpharma Biologics S.A.
Polpharma Biologics is an international biotechnology company with integrated operations in the European Union, developing and manufacturing biosimilar medicines. Using patented solutions and state-of-the-art platform technologies, Polpharma Biologics develops biosimilar products to treat a range of conditions in major therapeutic areas. Programs at Polpharma Biologics start in cell line development and transition through technical and clinical development to commercial-scale production ready to be commercialized by our partners in all major pharmaceutical markets. The company’s expertise is in the development and manufacturing of medicines based on microbial & mammalian expression. Company is currently developing 10 molecules and in addition, have 2 biosimilars approved in multiple markets. These leading biosimilars are partnered with multiple companies for marketing rights to different territories.
PharSafer
Founded in 2003 by Dr Graeme Ladds, PharSafer® is a specialist Contract Research Organisation (CRO) in Global Clinical and Post Marketing Drug Safety, and Medical Services, with a wealth of experience in Pharmacovigilance, Auditing and Medical Affairs – and the various, numerous and extensive legal safety/medical obligations for licence holders to comply with – as well as Regulatory Strategy for the best methods for obtaining scientific advice concerning licence submissions and approvals. Together with our sister company which focuses on Training: SaPhar, PharSafer® continuously seeks new and innovative ways to provide added value for our global clients – going above and beyond expectations and optimising processes and procedures involved with clinical and post marketing drug safety and licencing approach. Our ability to offer first-class services in Pharmacovigilance, Regulatory Affairs, Training, Auditing, Medical Affairs and IT Informatics means that, for many clients, we operate as their Pharmacovigilance and Medical Departments – guiding them through the labyrinth of drug safety and medical legislation, all in the interests of ensuring patient safety and client compliance. We love what we do. We love finding solutions. Quite simply, we are by far… Your leading partner in Drug Safety. | PharSafer is a Global CRO specialising in Clinical & Post Marketing Pharmacovigilance; Medical Affairs; Training; Auditing; IT Informatics and Regulatory Intelligence. PharSafer have been operating for the last 23 years growing annually and helping take Companies from their clinical to post-marketing phases and many clients have been with us over 10 years now. PharSafer have attended over 100 inspections on behalf of clients to aid their compliance and ensure Regulatory Authorities are satisfied with the activities being performed. PharSafer are also an innovative Company designing validated and automated systems to provide cost-effective solutions for clients and ensure Regulatory compliant systems. Our client base is truly global being in all continents and for clients that have drugs; devices; vaccines; biologics; advanced therapies; biosimilars; herbal and cosmetics. Our Team within the Company are very experienced (many with over 15 years experience) aided by our sister training Company (SaPhar) to provide new updates for clients on country specific regulations with regular monthly contacts and comments going to all clients. We would be happy to engage with you and talk about product development; product expansions into new countries; product launches and perform all of the activities mentioned above. Please review of website and we look forward to engaging with you personally.
Pharmasaga Co. Ltd.
Pharmasaga Co. Ltd. (https://www.pharmasaga.com/en/index.aspx), is a drug discovery and development company. It aims to develop novel anti-diabetic small-molecule drugs that can treat and reverse diabetes. Pharamsaga pioneered to study function and mechanism of Pdia4, a master gene that controls β-cell pathogenesis and, in turn, diabetes. Using a rational drug design strategy, combining molecular docking, Pdia4 bioassay, and chemical synthesis, PS1, a Pdia4-based drug candidate, was developed for diabetes. This novel drug precisely targets diabetes and has the potential to become the world’s first curative treatment for diabetes. After receving IND approvals from the USFDA and Taiwanese FDA, PS1 is now on human trials for type 2 diabetes, followed by human trials for type 1 diabetes and pancreatic cancer. Preliminary data showed that PS1 had high safety and great efficacy in decreased blood glucose. Additionally, Orphan Drug Designation (ODD) of PS1 was applied to USFDA.
Pharmascience
Pharmascience, founded in 1983, is a manufacturer of high quality generic products. Our fully integrated Canadian specialty division, Pendopharm, is a leader in commercializing innovative and value-added medicines that address unmet medical needs across key therapeutic areas. With an impressive annual production of over 5 billion doses and distribution spanning more than 50 countries, we offer 1,300 distinct high-quality products in various dosage forms. Additionally, our services extend to sterile injectable CDMO (Contract Development and Manufacturing Organization) for both the Canadian and international markets. Thanks to substantial investments totaling $150 million, we have tripled our sterile injectable capacity, enabling us to provide a comprehensive range of services for prefilled syringes, liquid vials, and lyophilized vials. We eagerly look forward to connecting with you, whether in person or through the partnering app! | Since 1983, Pharmascience has been a leading manufacturer of generic, branded, and over-the-counter pharmaceuticals, serving both the Canadian and international markets. With product distribution in over 50 countries, we provide more than 1,400 different high-quality products to pharmaceutical wholesalers, hospitals, and pharmacists. Our facilities produce more than 5 billion dosage units of medicines every year.
Perseo pharma AG
Gut Restricted Metabolic Therapies Perseo Pharma is a biopharmaceutical company pioneering innovative metabolic therapies. Founded in 2019 in Europe’s leading Life Science hub, Perseo has assembled a world-class team and state-of-the-art facilities. The company has raised CHF 10 million from private investors, including a U.S. patient advocacy organization and a corporate fund. Perseo’s proprietary platform technology enables the development of highly effective gut-restricted treatments for a range of metabolic disorders. The company is targeting conditions like Exocrine Pancreatic Insufficiency (EPI) and a family of rare diseases made of Intoxication-Type Inborn Errors of Metabolism, including Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Congenital Sucrase-Isomaltase Deficiency (CSID), and Tyrosinemia. Each of these represents a market worth over $1 billion, and the compounds we are developing for these indications are eligible to Orphan Drug Designation (ODD). PER301, Perseo’s lead compound for EPI (well established $1.5bn market in the US alone), is being developed in partnership with Nestlé Health Science. A significant commercial milestone for this collaboration is anticipated within 6-9 months. With a second partnership in place with another biotech company for IBD, an excellent partnering track record, and a unique platform, Perseo is the partner of choice for the joint development of gut-restricted metabolic therapies. We are currently raising our Series A of CHF 8M, for which we have signed a Term Sheet with a US-based Lead Investor.